Brooks Laboratories Limited (NSE:BROOKS)
India
· Delayed Price · Currency is INR 58.46
-2.54 (-4.16%)
Mar 9, 2026, 3:29 PM IST
Brooks Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 888.46 | 825.57 | 794.86 | 632.05 | 911.85 | 772.47 | Upgrade
|
| Revenue Growth (YoY) | 15.44% | 3.86% | 25.76% | -30.69% | 18.04% | 10.85% | Upgrade
|
| Cost of Revenue | 549.62 | 546.21 | 569.73 | 524.09 | 639.79 | 485.69 | Upgrade
|
| Gross Profit | 338.84 | 279.36 | 225.13 | 107.95 | 272.06 | 286.78 | Upgrade
|
| Selling, General & Admin | 150.07 | 132.73 | 107.94 | 176.94 | 194.68 | 146.43 | Upgrade
|
| Other Operating Expenses | 106.12 | 93.82 | 78.14 | 194.77 | 217.67 | 134.57 | Upgrade
|
| Operating Expenses | 271.83 | 242.56 | 203.82 | 441.97 | 485.86 | 352.44 | Upgrade
|
| Operating Income | 67.01 | 36.81 | 21.32 | -334.02 | -213.8 | -65.66 | Upgrade
|
| Interest Expense | -8.29 | -8.5 | -7.25 | -19.54 | -28.31 | -30.98 | Upgrade
|
| Interest & Investment Income | 2.95 | 2.95 | 1.07 | 1.27 | 0.91 | 1.85 | Upgrade
|
| Earnings From Equity Investments | 150.75 | -129.84 | -211.21 | -33.1 | - | -0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.4 | 1.4 | 1.53 | -0.43 | 2.22 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.91 | -1.78 | -1.2 | -1.53 | -1.31 | 5.51 | Upgrade
|
| EBT Excluding Unusual Items | 216.72 | -98.97 | -195.74 | -387.35 | -240.29 | -89.37 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.08 | 0.08 | 0.08 | 0.08 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.1 | 0.1 | - | - | 1.31 | -0.56 | Upgrade
|
| Other Unusual Items | 0.88 | 0.88 | - | 3.57 | - | - | Upgrade
|
| Pretax Income | 217.78 | -97.92 | -195.66 | -383.7 | -238.98 | -89.93 | Upgrade
|
| Income Tax Expense | 1.75 | 1.75 | 0.26 | -73.24 | -45.85 | 103.82 | Upgrade
|
| Earnings From Continuing Operations | 216.03 | -99.67 | -195.92 | -310.46 | -193.13 | -193.76 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 101.54 | 80.23 | - | Upgrade
|
| Net Income | 216.03 | -99.67 | -195.92 | -208.92 | -112.9 | -193.76 | Upgrade
|
| Net Income to Common | 216.03 | -99.67 | -195.92 | -208.92 | -112.9 | -193.76 | Upgrade
|
| Shares Outstanding (Basic) | 29 | 27 | 26 | 25 | 25 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 29 | 27 | 26 | 25 | 25 | 25 | Upgrade
|
| Shares Change (YoY) | 11.78% | 4.59% | 3.70% | - | - | 40.27% | Upgrade
|
| EPS (Basic) | 7.40 | -3.72 | -7.65 | -8.46 | -4.57 | -7.84 | Upgrade
|
| EPS (Diluted) | 7.40 | -3.72 | -7.65 | -8.46 | -4.57 | -7.84 | Upgrade
|
| Free Cash Flow | - | 17.04 | -102.4 | -149.58 | -650.53 | -11.55 | Upgrade
|
| Free Cash Flow Per Share | - | 0.64 | -4.00 | -6.05 | -26.33 | -0.47 | Upgrade
|
| Gross Margin | 38.14% | 33.84% | 28.32% | 17.08% | 29.84% | 37.13% | Upgrade
|
| Operating Margin | 7.54% | 4.46% | 2.68% | -52.85% | -23.45% | -8.50% | Upgrade
|
| Profit Margin | 24.32% | -12.07% | -24.65% | -33.05% | -12.38% | -25.08% | Upgrade
|
| Free Cash Flow Margin | - | 2.06% | -12.88% | -23.67% | -71.34% | -1.49% | Upgrade
|
| EBITDA | 78.02 | 49.45 | 36.15 | -267.44 | -143.15 | 3.15 | Upgrade
|
| EBITDA Margin | 8.78% | 5.99% | 4.55% | -42.31% | -15.70% | 0.41% | Upgrade
|
| D&A For EBITDA | 11.01 | 12.65 | 14.83 | 66.58 | 70.65 | 68.82 | Upgrade
|
| EBIT | 67.01 | 36.81 | 21.32 | -334.02 | -213.8 | -65.66 | Upgrade
|
| EBIT Margin | 7.54% | 4.46% | 2.68% | -52.85% | -23.45% | -8.50% | Upgrade
|
| Effective Tax Rate | 0.80% | - | - | - | - | - | Upgrade
|
| Revenue as Reported | 901.98 | 834.4 | 804.04 | 634.16 | 919.86 | 779.82 | Upgrade
|
| Advertising Expenses | - | 2.97 | 2.45 | 3.43 | 2.6 | 2.57 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.